Galapagos Advances GLPG4617 Into Phase 2 Trial

Galapagos Advances GLPG4617 Into Phase 2 Trial

293993

Galapagos Advances GLPG4617 Into Phase 2 Trial

In a move that refocuses its clinical pipeline, Galapagos is discontinuing the development of GLPG1205, its experimental therapy for idiopathic pulmonary fibrosis (IPF), and advancing its most recent IPF candidate, GLPG4617, into a Phase 2 clinical trial. These and other decisions toward a “more risk-balanced pipeline” are expected to generate savings of €150 million (about $182 million) over one year. This IPF pipeline trimming comes nearly three months after the company announced discontinuation of the clinical…

You must be logged in to read/download the full post.